Application of adjuvant therapy for melanoma into clinical practice
October 28, 2020
This recent article provides an opinion on the application of adjuvant therapy for melanoma in clinical practice. It covers:
- How the data relates to the new AJCC 8th edition staging system
- Adjuvant treatment if the disease is BRAF mutation positive
- “Second adjuvant” therapy
- Management of unresectable recurrence on adjuvant therapy
- Adjuvant therapy toxicity
- Dosing schedules for adjuvant immunotherapy
- Patients with stage IIB and IIC melanoma and adjuvant therapy
- Current practice not to perform an immediate completion lymph node dissection: impact on
outcomes - Non-cutaneous melanoma
- Adjuvant therapy for other special patient groups
- Future directions
Source:
Tharani Krishnan , Alexander M Menzies & Rachel Roberts-Thomson (2020):
Applying adjuvant therapy for melanoma into clinical practice, Expert Review of Anticancer
Therapy, DOI: 10.1080/14737140.2021.1841641